Skip to main content

Branded

  • Lilly, Boehringer Ingelheim launch Lantus follow-on Basaglar

    INDIANAPOLIS and RIDGEFIELD, Conn. — Eli Lilly and Co. and Boehringer Ingelheim Pharmaceuticals on Thursday announced the launch and availability of their Basaglar. The drug is a follow-on insulin to U-100 insulin glargine Lantus and is a long-acting insulin with an amino acid sequence identical to that of Lantus. 
     

  • FDA approves Pfizer’s eczema treatment Eucrisa

    SILVER SPRING, Md. — The Food and Drug Administration on Wednesday announced its approval of Pfizer’s Eucrisa (crisaborole). The ointment is indicated to treat mild to moderate eczema in patients two years of age and older. 
     

  • FDA approves Synjardy XR from Lilly, Boehringer Ingelheim

    RIDGEFIELD, Conn. and INDIANAPOLIS — The Food and Drug Administration has approved Eli Lilly & Co.’s and Boehringer Ingelheim’s Synjardy XR (empagliflozin and metformin hydrochloride) extended-release tablets. The drug is indicated to improve blood sugar in adults with Type 2 diabetes when both empagliflozin and metformin can be taken. 
     

  • Lilly rolls out insulin discount program

    INDIANAPOLIS, Ind. —  Eli Lilly & Co. has outlined a new initiative, set to begin Jan. 1, 2017, that will offer access to Lilly insulin at discounted prices to patients via Blink Health’s mobile and web platforms through a partnership with Express Scripts. 
     

  • Lilly, AstraZeneca to team on Alzheimer’s treatment development

    INDIANAPOLIS — Eli Lilly and Co. and AstraZeneca are teaming up to co-develop a potential disease-modifying treatment for Alzheimer’s disease, the companies announced Friday. 
     
    The focus of the initiative, which will see Lilly making an upfront payment of $30 million to AstraZeneca, is an antibody called MEDI1814, which can potentially slow the progression of the illness and is currently in Phase 1 trials. 
     

  • Report: London Drugs could be first to market with medical marijuana

  • Endo shifts focus from pain to specialty in U.S. branded business, eliminates pain sales force

    DUBLIN — Endo is shifting the focus of its U.S. branded portfolio of drugs, starting with the return of rights to Belbuca (buprenorphine ) buccal film to BioDelivery Sciences International, which was announced Thursday. The company also announced that its pain portfolio no longer requires field sales promotion and is eliminating its 375-member U.S. branded pain sales field force. 
     

  • Report: AstraZeneca to shed 700 U.S. jobs

    WILMINGTON, Dela. — AstraZeneca is set to eliminate some 700 positions in the U.S. by the early months of 2017, according to reports. The company told USA Today the cuts would take effect Feb. 10, with its Fairfax, Delaware headquarters seeing about 120 of the expected cuts, with other impacted roles spanning those that are field-based in both sales and non-sales. 
     
X
This ad will auto-close in 10 seconds